* Takeda is selling non-core assets after $59 bln Shire purchase
* Deal left Takeda highly indebted
* Sale expected to close in quarter ending March
* Takeda will continue to make the drugs for Acino (Adds further detail of sale)
TOKYO, Oct 15 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd 4502.T said on Tuesday it will sell a portfolio of over-the-counter (OTC) and prescription medicines in the Middle East and Africa to Swiss pharmaceuticals company Acino for more than $200 million.
The sale, which Takeda said in a statement is expected to close in the quarter ending March, comes as Japan's biggest drugmaker looks to trim its debt following the $59 billion purchase of Shire. gained global heft through the Shire acquisition but left it highly indebted. It has pledged to shed non-core assets while focusing on five key areas - oncology, gastroenterology, neuroscience, rare disease, and plasma-derived therapies.
Takeda said it will continue to manufacture the drugs for Acino, which is backed by Avista Capital AVAAA.UL and Nordic Capital.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.